RVMD · Revolution Medicines, Inc.
$203.71
+1.71 (+0.85%)
At close · Aug 14
Market Cap
$43.66B
Shares
214.34M
Revolution Medicines, Inc. Earnings Call Transcripts
Every quarterly earnings call for Revolution Medicines, Inc. (RVMD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲204.8%
$3.36M
−$73.33M
'22 Q3
22-11-07
▲62.1%
$15.33M
−$56.51M
'22 Q4
23-02-27
▼7.4%
$7.01M
−$68.10M
'23 Q1
23-05-08
▼58.1%
$3.82M
−$98.30M
'23 Q2
23-08-08
▼100%
$
−$108.43M
'23 Q3
23-11-06
▼95.2%
$742,000
−$161.54M
'23 Q4
24-02-26
▼100%
$
−$116.00M
'24 Q1
24-05-08
▼100%
$
−$133.23M
'24 Q2
24-08-07
·
$
−$156.29M
'24 Q3
24-11-06
LATEST
▼100%
$
−$194.57M
'24 Q4
25-02-26
Earnings call
FY26 · Q2
2026-08-05
Revolution Medicines, Inc. Q2 FY2026 Earnings Call
Confident tone
Expanded Access Program (EAP)
Pancreatic cancer / PDAC launch
Regulatory progress
Diluted EPS
$-3.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-31
Revolution Medicines Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Revolution Medicines, Inc. Q1 FY2026 Earnings Call
Confident tone
RASolute 302 Phase 3 results in pancreatic cancer
Pipeline of RAS(ON) inhibitors and combination strategies
Clinical and competitive uncertainties
Diluted EPS
$-2.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Revolution Medicines, Inc. Q4 FY2025 Earnings Call
Confident tone
Daraxonrasib in pancreatic cancer (RASolute 302/303/304)
Zoldonrasib development in PDAC
RMC-6236 (daraxonrasib) combination strategies
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Revolution Medicines, Inc. Q3 FY2025 Earnings Call
Confident tone
Daraxonrasib in pancreatic cancer (PDAC)
Combination strategies and resistance mechanisms
Efficacy and durability data
Diluted EPS
$-1.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Revolution Medicines, Inc. Q2 FY2025 Earnings Call
Confident tone
Pancreatic cancer program (daraxonrasib)
Non-small cell lung cancer (NSCLC)
Clinical collaborations and combinations
Diluted EPS
$-1.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Revolution Medicines, Inc. Q1 FY2025 Earnings Call
Confident tone
Non-small cell lung cancer strategy
RAS(ON) inhibitor portfolio
Pancreatic cancer development
Diluted EPS
$-1.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Revolution Medicines, Inc. Q4 FY2024 Earnings Call
Confident tone
RAS(ON) inhibitor pipeline progress
Combination strategies
Pivotal/registrational trials execution
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Revolution Medicines, Inc. Q3 FY2024 Earnings Call
Confident tone
RMC-6236 in pancreatic cancer (PDAC)
Combination strategy and clinical collaborations
Non-small cell lung cancer strategy
Revenue
$
Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Revolution Medicines, Inc. Q2 FY2024 Earnings Call
Confident tone
RMC-6236 pancreatic cancer data and registrational plans
Combination studies and early-line expansion
RAS(ON) mutant-selective inhibitors (RMC-6291, RMC-9805)
Revenue
$
▼ 100% YoY Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Revolution Medicines, Inc. Q1 FY2024 Earnings Call
Confident tone
RMC-6236 combination regimens
RMC-6236 pivotal trial strategy
RMC-6291 and RMC-9805 mutant-selective inhibitors
Revenue
$
▼ 100% YoY Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Revolution Medicines, Inc. Q4 FY2023 Earnings Call
Confident tone
RMC-6236 pivotal trial plans
Financial strength and runway
RMC-6291 G12C selective inhibitor
Revenue
$742,000*
▼ 95.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Revolution Medicines, Inc. Q3 FY2023 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-0.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Revolution Medicines, Inc. Q2 FY2023 Earnings Call
Revenue
$3.82M
▼ 58.1% YoY Diluted EPS
$-0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Revolution Medicines, Inc. Q1 FY2023 Earnings Call
Revenue
$7.01M
▼ 7.4% YoY Diluted EPS
$-0.72
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Revolution Medicines, Inc. Q4 FY2022 Earnings Call
Revenue
$15.33M*
▲ 62.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Revolution Medicines, Inc. Q3 FY2022 Earnings Call
Revenue
$3.36M
▲ 204.8% YoY Diluted EPS
$-0.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Revolution Medicines, Inc. Q2 FY2022 Earnings Call
Revenue
$9.12M
▲ 4.8% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Revolution Medicines, Inc. Q1 FY2022 Earnings Call
Revenue
$7.58M
▼ 25.2% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Revolution Medicines, Inc. Q4 FY2021 Earnings Call
Revenue
$9.46M*
▲ 8.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Revolution Medicines, Inc. Q3 FY2021 Earnings Call
Revenue
$1.10M
▼ 91.3% YoY Diluted EPS
$-0.72
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Revolution Medicines, Inc. Q2 FY2021 Earnings Call
Revenue
$8.70M
▼ 13.2% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts
CIK
1628171
CUSIP
76155X100
13F (30d)
642 filings
634 filers
Visit website
Investor relations